News & Videos - SENSEONICS HOLDINGS INC.

Thinking about buying stock in Senseonics Holdings, Ainos, Marpai, Rush Street Interactive, or Evgo? PR Newswire NEW YORK, March 8, 2024 NEW YORK , March 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SENS, AIMD, MRAI, RSI, and EVGO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. SENS:...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the second quarter of 2023 Submitted an application to the FDA for an iCGM designation for the Eversense CGM system Received a positive...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, August 10, 2023. Management will hold a conference call to review the Company’s second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On July 3, 2023, Senseonics Compensation Committee granted 4 new non-executive employees non-qualified...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted new clinical data presented at the American Diabetes Association 83 rd Scientific Session. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system. “These data further bolster Eversense’s position as a leading CGM...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that UnitedHealthcare, the largest health insurance company in the United States, will begin providing coverage for the Eversense E3 CGM System effective July 1, 2023 for people with type 1 and insulin-requiring type 2 diabetes. "The policy update from...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Jefferies Healthcare Conference in New York, NY. Management is scheduled to present on Friday, June 9, 2023, from 9:30am to 9:55am ET. Interested parties may access a live and recorded webcast of the presentation on the...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended March 31, 2023. Recent Highlights & Accomplishments: Generated revenue of $4.1 million in the first quarter of 2023. Ascensia Diabetes Care, Senseonics’ global commercial partner, is expanding their U.S. salesforce to a...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2023 financial results after market close on Tuesday, May 9, 2023. Management will hold a conference call to review the Company’s first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The...

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the first pediatric study participant has been inserted with Eversense® 365-day system as part of the pivotal ENHANCE clinical trial at the AMCR Institute, a clinical research center focused on pre-diabetes, type 1, type 2 diabetes and obesity, under the direction...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On April 4, 2023, Senseonics Compensation Committee granted thirteen new non-executive employees, in the...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2022. Recent Highlights & Accomplishments: Generated fourth quarter 2022 revenue of $5.6 million and full year 2022 revenue of $16.4 million. Achieved full year of gross profit for the first time in...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a joint virtual analyst and investor event alongside PHC Holdings Corporation, the parent company of Senseonics’ global commercial partner, Ascensia Diabetes Care, on Wednesday, March 15, 2023 at 6:30pm ET. The event will include presentations from...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section 711(a). On January 5, 2023, the Senseonics Compensation Committee granted 10 new non-executive employees...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel Healthcare Conference in New York, NY. Management is scheduled to participate on Tuesday, November 15, 2022 at 11:30am ET and will hold one-on-one meetings following. Interested parties can access a live and recorded...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended September 30, 2022. Recent Highlights & Accomplishments: Launched collaboration with the Nurse Practitioner Group designed to expand U.S. patient access to Senseonics’ six-month Eversense E3 System by providing additional...

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM) PR Newswire GERMANTOWN, Md., Nov. 3, 2022 First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense ® E3 CGM GERMANTOWN, Md. , Nov. 3, 2022 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, and Ascensia Diabetes Care, a global diabetes care company, maker of the CONTOUR® blood glucose monitoring (BGM) system portfolio and exclusive distributor of Eversense® CGM Systems, today announced the launch of a collaboration with the Nurse Practitioner Group (NPG), a leader...

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM) PR Newswire GERMANTOWN, Md., Nov. 3, 2022 First patients have been served, launching the Nurse Practitioner Group partnership to expedite and expand access to the Eversense ® E3 CGM GERMANTOWN, Md. , Nov. 3, 2022 /PRNewswire/ -- Senseonics Holdings, Inc. (NYSE...

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022. Management will hold a conference call to review the Company’s third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day....